Bloomberg Law
Nov. 29, 2021, 8:37 PMUpdated: Nov. 30, 2021, 3:50 PM

Pfizer, Merck Pills Renew Concerns on Covid Treatment Equity (1)

Ian Lopez
Ian Lopez
Senior Reporter

Pfizer’s and Merck’s rollouts of Covid-19 treatment pills threaten to exacerbate inequities in pandemic treatment access as the global community braces for the impact of the new omicron virus variant.

Licensing agreements with the UN-backed Medicines Patent Pool open the doors for multiple generic drug producers to put out their own versions of Pfizer Inc.'s and Merck & Co.'s pills to treat those infected with Covid-19 in overseas markets.

The moves throw lifelines to low-income countries across the globe, with Pfizer boasting coverage of over 50% of the world’s population and Merck creating access for over 100 low- and middle-income ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.